絞り込み

16645

広告

「"Fahrleitner-Pammer A "[Author]」の検索結果

117件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture - Results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS).

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial.

Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women.

Bone matrix hypermineralization associated with low bone turnover in a case of Nasu-Hakola disease.

Teriparatide treatment increases mineral content and volume in cortical and trabecular bone of iliac crest: a comparison of infrared imaging with X-ray-based bone assessment techniques.

The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance.

Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.

Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry.

A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder.

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.

Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.

Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial.

Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります